| Literature DB >> 20540739 |
Javier Del Rey1, Esther Prat, Immaculada Ponsa, Josep Lloreta, Antoni Gelabert, Ferran Algaba, Jordi Camps, Rosa Miró.
Abstract
BACKGROUND: Aneuploidy, centrosome abnormalities and gene amplification are hallmarks of chromosome instability (CIN) in cancer. Yet there are no studies of the in vivo behavior of these phenomena within the same bladder tumor.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20540739 PMCID: PMC2906479 DOI: 10.1186/1471-2407-10-280
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Patient characteristics and study results
| Case | Age/Sex | Stage/Grade | S/M | CIS | Modal number Chr 11 | CIN index | CGH 11q13 | FISH | Subpop | SC (%) | C size (μm) | AC | MS (%) | Recurrence (months) | Survival | CRD | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45/♂ | TaG1 | S | - | 2 | 17.64 | normal | normal | No | 0 | 0.8 | - | 0 | 0 | >6 years | No | ||
| 63/♀ | TaG1 | S | - | 2 | 20 | normal | normal | No | 3.8 | 1.10 | - | 0 | 1;(19) | >6 years | No | ||
| 66/♂ | TaG2 | S | + | 2 | 20.18 | normal | normal | No | 0 | 0.98 | - | 0 | 3;(4),(60),(8) | >6 years | No | ||
| 68/♂ | T1G2 | M | - | 2 | 23.97 | gain | gain | No | 1 | 0.63 | - | 0 | 5;(8),(15),(34),(43),(3) | >5 years | No | ||
| 52/♀ | TaG2 | M | - | 2 | 25.9 | normal | normal | No | 0 | 0.9 | - | 0 | 1;(37) | >6 years | No | ||
| 58/♂ | TaG1 | S | - | 2 | 25.41 | normal | normal | No | 1 | 0.81 | - | 0 | 1;(67) | >5 years | No | ||
| 68/♂ | TaG1 | S | + | 2 | 28.75 | normal | normal | No | ? | ? | ? | ? | 1;(28) | >6 years | No | ||
| 54/♂ | T1G3 | S | + | 2 | 33.7 | normal | normal | No | 0 | 2.04 | + | 0 | 0 | >42 months | No | ||
| 62/♂ | T1G3 | S | - | 2 | 34.16 | amp | HSR | Yes (3) | 0 | 0.98 | - | 0 | 3;(17),(13)*,(34)* | 67 months | Yes | ||
| 48/♂ | TaG1 | S | - | 2 | 37.91 | normal | normal | No | 0 | 0.8 | - | 0 | 0 | >6 years | No | ||
| 45/♂ | TaG2 | S | - | 2 | 43.33 | normal | normal | No | 5 | 1.21 | + | 0 | 2;(8),(13) | >5 years | No | ||
| 60/♂ | T1G2 | S | - | 2 | 43.51 | amp | HSR, DM | Yes (2) | 21 | 4.88 | + | 0 | 5;(10),(17),(9),(6),(7) | 54 months | Yes | ||
| 67/♂ | TaG1 | S | - | 2 | 47.5 | normal | normal | No | ? | ? | ? | ? | 2;(9),(11) | >6 years | No | ||
| 73/♂ | T1G2 | S | + | 2 | 54.83 | normal | normal | No | 4 | 1.06 | - | 0 | 0 | >41 months | No | ||
| 51/♂ | T1G3 | M | + | 2 | 57.14 | normal | gain | No | 38 | 0.68 | + | 7 | 0 | >6 years | No | ||
| 67/♂ | T1G3 | M | + | 2 | 60.41 | amp | HSR, DM | Yes (2) | 20 | 2.22 | + | 17 | 3;(9),(4),(10) | 31 months | Yes | ||
| 40/♂ | T1G3 | M | + | 3 | 65.68 | normal | gain, HSR, DM | Yes (3) | 0 | 5.69 | + | 0 | - | 36 months | Yes | ||
| 73/♂ | T1G3 | S | - | 2 | 67.61 | normal | gain, HSR1, HSR2 | Yes (3) | 27 | 2.06 | + | 17 | 0 | >3 months | No | ||
| 62/♂ | T1G3 | M | + | 3 | 70 | normal | HSR | No | 5 | 1.18 | + | 0 | 0 | >6 years | No | ||
| 71/♂ | T1G2 | S | - | 4 | 70.66 | gain | gain | No | ? | ? | ? | ? | 1;(14) | >6 years | No | ||
| 55/♂ | T1G2 | S | - | 2 | 70.68 | loss | gain | No | 0 | 2.01 | + | 0 | 2;(10),(3) | >6 years | No | ||
S: single, M: multiple, CIS: carcinoma in situ, CIN index: percentage of cells not displaying the modal copy number for chromosome 11, subpop: presence and number of intratumor subpopulations, defining subpopulation as a group of cells with a distinctive chromosomal alteration (numerical or structural) at a specific area on the tumor, amp: amplification, HSR: homogeneously staining region, HSR1,2: different types of homogeneously staining region, DM: double minute, SC: percentage of cells displaying supernumerary centrosomes (>2 centrosomes), C size: average size of centrosome, AC: presence of abnormal centrosomes (size >2 μm or number >2 in at least 5% of cells), MS: percentage of cells displaying multipolar spindle, *: metastasis, CRD: cancer related death, ?: data not available
Figure 1Chromosome 11 copy number variability. (A) Negative-CIN tumors. (B) Moderate-CIN tumors. (C) High-CIN tumors. (D) CIN index vs. tumour grade correlation.
Figure 2Centrosome abnormalities. Immunolabeling was performed for γ-tubulin (red) and α and β-tubulin (green). DNA staining was performed with DAPI (blue). Black and white images correspond to DAPI reverse staining. (A-B) Normal/bipolar spindle. (C-D) Bipolar metaphase with string-like centrosome. (E) Tumour cells with abnormally long centrosomes, close to the adjacent normal urothelium. (F-G) Multipolar spindle. (H-I) Pseudo-bipolar metaphase. (J) Tumour cells with supernumerary centrosomes. Scale bar, 3 μm.
Figure 3. FISH identification of chromosome 11 centromere (green) and CCND1 gene (red) in paraffin-embedded tumors. DNA staining was performed with DAPI (blue). Black and white images correspond to DAPI reverse staining. (A-H) Metaphasic cells showing the proposed sequence of 11q13 amplicon fragmentation from HSRs to DMs. (I-K) Sample U-364 showed a complex pattern of CCND1 amplification. Three sub-populations were detected in this sample. (I) Sub-population with gain of whole chromosome 11. (J) Sub-population containing HSR with high-level amplification of CCND1 (K) Sub-population containing amplification of CCND1 and undetermined flanking material in HSR. (L-O) Peripheral location of DMs in metaphasic cells. (P-Q) CCND1-positive micronuclei, see arrows. In Q, note the elimination in the micronucleus of whole CCND1 copies, except those attached to the centromere. (R) Metaphasic cells containing a dicentric chromosome with two centromeric signals of chromosome 11 and CCND1 amplification, see asterisks. (S and T) CCND1 with HSRs appears to be forming internuclear bridges, see arrows. (U and V) Nuclear blebs as nuclear protrusions with high CCND1 signal.
DM localization on metaphase plate and micronuclei frequencies
| 22/25 | 88.00% | 28/472 | 5.93% | 1/472 | 0.21% | 62/472 | 13.14% | |
| 27/36 | 75.00% | 19/477 | 3.98% | 1/477 | 0.21% | 48/477 | 10.06% | |
| 15/20 | 75.00% | 10/412 | 2.43% | 10/412 | 2.43% | 42/412 | 10.19% | |
DM: Double minute, MN: Miclonuclei, CEP: Centromere